| Literature DB >> 31266186 |
Bishweshwar Pant1, Mira Park2, Soo-Jin Park3.
Abstract
Electrospinning has emerged as one of the potential techniques for producing nanofibers. The use of electrospun nanofibers in drug delivery has increased rapidly over recent years due to their valuable properties, which include a large surface area, high porosity, small pore size, superior mechanical properties, and ease of surface modification. A drug loaded nanofiber membrane can be prepared via electrospinning using a model drug and polymer solution; however, the release of the drug from the nanofiber membrane in a safe and controlled way is challenging as a result of the initial burst release. Employing a core-sheath design provides a promising solution for controlling the initial burst release. Numerous studies have reported on the preparation of core-sheath nanofibers by coaxial electrospinning for drug delivery applications. This paper summarizes the physical phenomena, the effects of various parameters in coaxial electrospinning, and the usefulness of core-sheath nanofibers in drug delivery. Furthermore, this report also highlights the future challenges involved in utilizing core-sheath nanofibers for drug delivery applications.Entities:
Keywords: biomedical; coaxial spinning; core-sheath nanofibers; drug delivery; electrospinning
Year: 2019 PMID: 31266186 PMCID: PMC6680404 DOI: 10.3390/pharmaceutics11070305
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1(A) Schematic diagram showing the electrospinning setup and (B) various biomedical applications of electrospun nanofibers.
Effect of various parameters on the properties of electrospun nanofibers.
| Parameter | Effect | Reference |
|---|---|---|
| Applied voltage | High voltage generally reduces fiber diameter. | [ |
| Concentration of solution | A higher concentration results in higher nanofiber diameter and the chances of bead formation are less. High concentration may clog the nozzle whereas low concentration may lead to sputtering. | [ |
| Flow rate | Most flow rates are limited to 1 mL/h or lower. | [ |
| Inner diameter of needle | If large, beaded fiber may form. | [ |
| Conductivity of solution | High conductivity leads to thinner nanofibers with less chances of bead formation. | [ |
| Viscosity of solution | High viscosity leads to the formation of thicker and continuous nanofibers whereas low viscosity is associated with finer and shorter nanofibers. | [ |
| Tip-to-collector distance (TCD) | Longer distance results in thinner fibers. | [ |
| Humidity | If humidity is high, beads and pores may form on nanofibers. | [ |
| Volatility of the solvent | High volatility of the solvent is associated with higher chances of porosity and increased surface area. | [ |
| Temperature | Both environmental and working fluid temperatures affect the fiber formation. Generally, the diameters of the nanofibers are uniform at higher temperatures. | [ |
| Type of the collector | Smooth fibers can be obtained from metal collectors. | [ |
Figure 2Schematic view showing the encapsulation and release procedure [50].
Figure 3Schematic diagram showing the coaxial electrospinning system.
Figure 4(a) Digital photographs showing a typical one-fluid electrospinning process, (b) formation of Taylor cone, (c) connection of spinneret in coaxial electrospinning, (d) enlarge image of the working region, and (e) Taylor cone with yellow core fluid encapsulate by rose-bengal shell solution [57].
Various core-sheath nanofibers for drug delivery applications.
| Core Fluid | Sheath Fluid | Name of Drug | Application | Reference |
|---|---|---|---|---|
| PVA | PCL, | Metoclopramidehydrochloride | Drug delivery vehicle | [ |
| PVA | PMMA | Ciprofloxacin | Periodontal disease and skin, bone, and joint infections | [ |
| PVA | Chitosan | Doxorubicin | Chemotherapy against ovary cancer | [ |
| Silk fibroin | PVA | Rosuvastatin | For enhancing osteogenesis of human adipose-derived stem cells | [ |
| PCL | PCL | Ampicillin | Controlled release | [ |
| PCL | PCL | Dipyridamole | Controlled release | [ |
| PCL | Gelatin | Metronidazole | Controlled release | [ |
| PCL | PEG | Salicylic acid | Studying the relationship between shell thickness and drug release rate | [ |
| PCL | PCL | Ampicillin | Controlled release of a hydrophilic drug | [ |
| Protein | PCL-PEG | BSA or PDGF | Controlled release of growth factor | [ |
| Dextran | PCL, | Dextran | Controlled release of proteins and drugs for tissue engineering | [ |
| PEG | PCL | BSA | Controlled release | [ |
| pHMGCL, PVPD | PCL | rhTGF-β1 | Sustained release of growth factor | [ |
| PEO | PCL& PIPAAm/AAC-nanogels | MO | Thermally switched release | [ |
| PEO | Carboxymethyl cellulose | Tetracycline hydrochloride | Drug delivery study | [ |
| PEO | PCL-PEG | BMP-2 | Drug release for bone tissue | [ |
| PEO | PCL | FGF-2 | Growth factor delivery for fibroblast proliferation | [ |
| PEO | Eudragit S100 | Indomethacin, mebeverine hydrochloride | Site specific drug release | [ |
| PEG | PLA | Salicylic acid | Effect of pores in the drug release | [ |
| PEG | PBSc | Triclosan/Curcumin | Drug release | [ |
| PVP | CA | Amoxicillin | Hydrophilic drug release | [ |
| PVP | EC | Maraviroc and Metronidazole | Drug release | [ |
| PVP/GO | PCL | Vancomycin hydrochloride | Time-programmed biphasic drug release | [ |
| PVP or PCL | PVP | Quercetin or Tamoxifen citrate | Dissolution of poorly water-soluble drugs | [ |
| Ethyl cellulose | PVP | Ketoprofen | Drug release profile study | [ |
| Naringin-loaded PVP | poly(lactic-co-glycolic acid) | Naringin | Fabrication of anti-infective guided tissue regeneration mats with promoting tissue regeneration | [ |
| Zein | Acetic acid | Ferulic acid | Modified coaxial spinning. The effect of acetic acid to stabilize core fibers. | [ |
| Zein | Zein | Ketoprofen | Hydrophobic drug release from protein fiber | [ |
| Zein | PVP | Ketoprofen | Hydrophobic drug release from protein fiber | [ |
| Tetracycline hydrochloride/Ethanol | Zein, | Tetracycline hydrochloride | Drug release study | [ |
| PLGA | Collagen | Fibronectin and Cadherin 11 | Dual drug delivery vehicle | [ |
| PLLCL | Collagen | BMP2 | Dual drug delivery vehicle | [ |
| PLGA-HA | Collagen | Amoxicillin | Hydrophilic drug release from hydrophilic shell | [ |
| Silk/collagen blend | Polyethylene oxide | Flurbiprofen and Vancomycin | Programmable release of anti-inflammatory and anti-bacterial agents | [ |
| CA | CA | Ketoprofen | Drug release study | [ |
| CA | Acetone-DMAc-ethanol | Ketoprofen | Controlled release | [ |
| Sodiumhyaluronate | Cellulose acetate | Naproxen | Controlled release for wound dressing | [ |
| Gelatin | PLLCL | Insulin, Hydrocortisone, and Retinoic acid | Dual drug delivery system | [ |
| PDLLA | PHB | Dimethyl oxalylglycine | Controlled release of hygroscopic drug | [ |
| PMMA | Nylon | Ampicillin | Release of hydrophilic drug in hydrophobic solvent | [ |
| PolyCD | PMAA | Proprannodol hydrochloride | Controlled release of hydrophobic drug | [ |
| PLA | N-isopropylacrylamide | Combretastatin A4 | Thermo-sensitivity study | [ |
| Shellac | Ethanol/DMF | Ferulic acid | Colon targeted drug delivery | [ |
| IBU solution in HFIP | Gliadin | Ibuprofen | Drug release behavior study | [ |
| Gliadin | Gliadin | Ketoprofen | Drug release study | [ |
| AAm/BIS-AAm | PLCL | BSA | Protein release | [ |
Poly(vinyl)alcohol (PVA), polycaprolactone (PCL), poly (lactic-co-glycolic acid) (PLGA), poly-L-lactic acid (PLLA), polymethyl(methacrylate) (PMMA), polyethylene glycol (PEG), polyethylene oxide (PEO), polylactic acid (PLA), cellulose acetate (CA), poly(L-lactide-co-caprolactone) (PLCL), poly(L-lactic acid)-co-poly(ϵ-caprolactone)(PLLCL), poly-d,l-lactic acid (PDLLA), polyhydroxybutyrate (PHB), poly-cyclodextrin (polyCD), graphene oxide (GO), platelet-derived growth factor (PDGF), bovine serum albumin (BSA), bone morphogenic protein (BMP), fibroblast growth factor (FGF), acrylamide (AAm), N,N’-methylene bisacrylamide (BIS-AAm), stilbazole quaternized (SbQ), recombinant human transforming growth factor (rh TGF-β1), methyl orange (MO).
Figure 5(A) TEM image of poly(vinyl alcohol)/chitosan (PVA/CS) core-sheath nanofibers with different feed ratios of (a) 1:1, (b) 1:1.3, and (c) 1:1.6 and (B) drug release profiles [68]. Reprinted with the permission from Materials Science and Engineering: C. Copyright Elsevier, 2014.